<DOC>
	<DOCNO>NCT01107509</DOCNO>
	<brief_summary>This study gather data potential biomarkers treatment advance renal cell carcinoma ( kidney cancer ) investigate use indicator disease response . The result could eventually enable doctor match level therapy level biomarker individual basis increase chance disease response patient . This study also test new paradigm treatment approach advance kidney cancer use drug everolimus neo-adjuvant setting , overarch goal decrease cancer recurrence rate improve patient outcome survival .</brief_summary>
	<brief_title>Pilot Study Neo-Adjuvant Everolimus Treat Advanced Renal Cell Carcinoma - Analysis Biomarkers</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>At least 18 year age capable give informed consent Radiological evidence RCC consisting : CT scan stage T2 , T3 , T3a , T3b , T4 , stage T N1/ 2 and/ metastatic disease Having nephrectomy willing kidney biopsy ECOG score 0 1 Clear cell histology Negative HIV , Hepatitis B , Hepatitis C Negative pregnancy test woman childbearing potential Stage T1 disease without metastasis Abnormal laboratory value screen within follow range : Absolute neutrophil count ≤ 1.5 × 109/ L ; Platelet count ≤ 100 × 109/ L Leukocyte count ≤ 3 × 109/ L ; Hemoglobin ≤ 80 g/ L ; Serum creatinine ≥ 2.0 × upper normal limit ( UNL ) ; Total bilirubin ≤ 1.5 × UNL ; AST ALT ≤ 3.0 × UNL Fasting serum cholesterol ≤ 9.0 mmol/ L ; Fasting serum triglyceride ≥ 5.0 mmol/L Any major illness , base investigator 's judgment , substantially increase risk associate subject 's participation study Other currently active malignancy Currently take medication know interfere metabolism everolimus Receiving anticoagulation warfarin A history pulmonary hypertension interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>Metastatic</keyword>
	<keyword>everolimus</keyword>
	<keyword>neo-adjuvant</keyword>
	<keyword>biomarkers</keyword>
	<keyword>nephrectomy</keyword>
	<keyword>Locally advanced clear cell renal carcinoma</keyword>
	<keyword>Metastatic clear cell renal carcinoma</keyword>
	<keyword>Clear Cell Renal Carcinoma</keyword>
</DOC>